PA
RAPT

Parallel Advisors’s RAPT Therapeutics RAPT Stock Holding History

Parallel Advisors’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-85
Closed -$13.4K – 3487
2022
Q4 		$13.4K Hold
85
– – ﹤0.01% 1920
2022
Q3 		$16K Hold
85
– – ﹤0.01% 1793
2022
Q2 		$12K Hold
85
– – ﹤0.01% 1910
2022
Q1 		$15K Hold
85
– – ﹤0.01% 1847
2021
Q4 		$25K Hold
85
– – ﹤0.01% 1677
2021
Q3 		$21K Hold
85
– – ﹤0.01% 1720
2021
Q2 		$21K Hold
85
– – ﹤0.01% 1658
2021
Q1 		$15K Hold
85
– – ﹤0.01% 1742
2020
Q4 		$13K Sell
85
-529
-86% -$115K ﹤0.01% 1682
2020
Q3 		$158K Buy
614
+55
+10% +$12.2K 0.01% 637
2020
Q2 		$129K Buy
+559
New +$86.4K 0.01% 673

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Parallel Advisors's RAPT Position: Q1 2023 in Review

Parallel Advisors sold out of RAPT Therapeutics (RAPT) in Q1 2023, closing a stake of 85 shares — an estimated $13.4K sold.

Parallel Advisors first reported a position in RAPT in Q2 2020 and held it in 11 quarters. The position peaked at $158K in Q3 2020. 106 funds tracked by Wall St. Rank hold RAPT as of Q1 2023.

  • Parallel Advisors reported no remaining RAPT Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Parallel Advisors sold 85 RAPT Therapeutics shares in Q1 2023, an estimated $13.4K.
  • Parallel Advisors first reported a position in RAPT Therapeutics in Q2 2020 and held it in 11 quarters.
  • Parallel Advisors's RAPT Therapeutics position peaked at $158K in Q3 2020.
  • 106 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2023.

Based on Parallel Advisors's 13F filing for Q1 2023, filed 25 Apr 2023.